|Articles|December 15, 2002
- BioPharm International-12-15-2002
- Volume 15
- Issue 1
Guest Editorial: EPO Saga to Augur Regulatory Change?
Author(s)Gordon Kelley
by Gordon Kelley, BioPharm International magazine
Advertisement
Articles in this issue
about 23 years ago
BioPharm International Five-Year Article Indexabout 23 years ago
Evaluation of Extractables from Product-Contact Surfacesabout 23 years ago
Monitoring and Controlling Biocatalytic ProcessesNewsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Advertisement
Advertisement
Advertisement
Trending on BioPharm International
1
HHS Releases New Guidance on Lowering Prescription Drug Prices Through DTC Programs
2
Industrial-Scale Cell Therapy Automation Gains Traction with New Cellares Funding
3
AstraZeneca’s $15 Billion Investment Deepens China R&D and Manufacturing Footprint
4
FDA Fast Tracks Innovent’s Trispecific Antibody for Multiple Myeloma
5
